4503
Astellas Pharma Inc.
アステラス製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
1,296,163
Mar 2023
1,518,619
Mar 2024
1,603,672
Mar 2025
1,912,323
Mar 2026
2,139,245
Operating profit(million JPY)
Mar 2022
155,686
Mar 2023
133,029
Mar 2024
25,518
Mar 2025
41,039
Mar 2026
382,633
Operating profit margin(%)
Mar 2022
12.01
Mar 2023
8.76
Mar 2024
1.59
Mar 2025
2.15
Mar 2026
17.89
Profit before tax(million JPY)
Mar 2022
156,886
Mar 2023
132,361
Mar 2024
24,969
Mar 2025
31,237
Mar 2026
376,587
Profit(million JPY)
Mar 2022
124,086
Mar 2023
98,714
Mar 2024
17,045
Mar 2025
50,747
Mar 2026
291,535
Total assets(million JPY)
Mar 2022
2,332,395
Mar 2023
2,456,518
Mar 2024
3,569,603
Mar 2025
3,339,544
Mar 2026
3,567,042
Cash and cash equivalents(million JPY)
Mar 2022
315,986
Mar 2023
376,840
Mar 2024
335,687
Mar 2025
188,372
Mar 2026
281,605
Cash flows from operating activities(million JPY)
Mar 2022
257,444
Mar 2023
327,767
Mar 2024
172,475
Mar 2025
194,512
Mar 2026
560,188
Cash flows from investing activities(million JPY)
Mar 2022
-62,413
Mar 2023
-84,500
Mar 2024
-845,802
Mar 2025
-89,419
Mar 2026
-66,722
Cash flows from financing activities(million JPY)
Mar 2022
-216,298
Mar 2023
-195,623
Mar 2024
614,060
Mar 2025
-261,367
Mar 2026
-404,779
Return on equity(%)
Mar 2022
8.7
Mar 2023
6.7
Mar 2024
1.1
Mar 2025
3.3
Mar 2026
17.4
Equity ratio(%)
Mar 2022
62.6
Mar 2023
61.4
Mar 2024
44.7
Mar 2025
45.3
Mar 2026
51.3
Earnings per share(JPY per share)
Mar 2022
67.08
Mar 2023
54.24
Mar 2024
9.51
Mar 2025
28.35
Mar 2026
162.77
Net assets per share(JPY per share)
Mar 2022
799.26
Mar 2023
839.26
Mar 2024
890.07
Mar 2025
845.25
Mar 2026
1,020.96
Dividend per share(JPY per share)
Mar 2022
50
Mar 2023
60
Mar 2024
70
Mar 2025
74
Mar 2026
78
Payout ratio(%)
Mar 2022
74.54
Mar 2023
110.62
Mar 2024
736.07
Mar 2025
261.02
Mar 2026
47.92
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.